QuantHealth Raises $45M Series B to Advance AI-Powered Clinical Trial Simulation

QuantHealth Secures $45 Million Series B

AI healthcare startup QuantHealth has raised $45 million in Series B funding to expand its AI-powered clinical trial simulation platform, helping pharmaceutical companies predict trial outcomes before enrolling patients.

The funding will support further development of its simulation technology as the pharmaceutical industry looks to reduce costly trial failures and accelerate drug development.

Note: The source provided confirms the $45M Series B but does not identify the lead investor or participating investors.

Using AI to Simulate Clinical Trials

QuantHealth's platform enables pharmaceutical companies to simulate clinical trials using AI, real-world data, and predictive models before launching studies in human participants.

The platform helps organizations:

• Predict patient responses to therapies

• Identify optimal patient populations

• Forecast potential adverse events

• Optimize trial protocols before recruitment

• Reduce avoidable clinical trial failures

By testing multiple scenarios virtually, companies can refine trial designs before making significant clinical investments.

Addressing High Clinical Trial Failure Rates

Clinical development remains one of the most expensive and uncertain stages of drug discovery, with approximately 90% of drugs entering Phase I failing to reach regulatory approval, according to the source.

QuantHealth aims to improve these outcomes by providing predictive insights that help pharmaceutical companies make better-informed decisions during trial planning.

Accelerating Drug Development

The newly raised capital will be used to strengthen QuantHealth's AI platform and expand its ability to support pharmaceutical companies throughout the clinical development process.

The company's technology integrates:

• Real-world clinical data

• Electronic health records

• Scientific literature

• Predictive AI models

to generate virtual simulations that support smarter trial design and decision-making.

Growing Role of AI in Clinical Research

As pharmaceutical companies increasingly adopt AI across drug development, virtual trial simulation is emerging as a promising approach for improving efficiency, reducing costs, and shortening development timelines.

The technology may also help identify biomarkers, optimize patient selection, and improve the likelihood of successful clinical outcomes while supporting more informed regulatory and commercial planning.